retatrutide cagrilintide Cagrilintide, Tirzepatide, and Peptides: Comparing Metabolic Mechanisms Cagrilintide + Retatrutide (Reta) Peptide

Dehydration worsens every GI side effect and is a common cause of the headaches associated with GLP-1 therapy

2023a, 2024a, 2024b)

Persistent vomiting defined as inability to keep down food or fluids for more than 24 hoursrequires immediate contact with your healthcare provider

Subcutaneous Beneath the skin but above the muscle layer

Methods for evaluating penetration of drug into the skin: A review

Retatrutide Dosage Based on Clinical Studies: The Scientific Foundation Dosing guidelines for retatrutide are based on the Phase 2 data published by Jastreboff and colleagues in NEJM (2023) and, as of 2026, on the first Phase 3 data from TRIUMPH-4